Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALNY NASDAQ:BMRN NASDAQ:CVAC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNYAlnylam Pharmaceuticals$279.59-0.8%$302.95$276.94▼$495.55$37.28B0.291.24 million shs824,403 shsBMRNBioMarin Pharmaceutical$54.81-0.6%$54.35$49.26▼$66.28$10.59B0.252.09 million shs984,768 shsCVACCureVac$4.66$4.66$3.13▼$5.72$1.05B1.77992,546 shsN/ATen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNYAlnylam Pharmaceuticals-2.05%-5.30%-1.77%-10.45%-8.71%BMRNBioMarin Pharmaceutical-0.95%-4.82%+6.39%-0.56%-1.99%CVACCureVac0.00%0.00%0.00%0.00%-15.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNYAlnylam Pharmaceuticals$279.59-0.8%$302.95$276.94▼$495.55$37.28B0.291.24 million shs824,403 shsBMRNBioMarin Pharmaceutical$54.81-0.6%$54.35$49.26▼$66.28$10.59B0.252.09 million shs984,768 shsCVACCureVac$4.66$4.66$3.13▼$5.72$1.05B1.77992,546 shsN/ATen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNYAlnylam Pharmaceuticals-2.05%-5.30%-1.77%-10.45%-8.71%BMRNBioMarin Pharmaceutical-0.95%-4.82%+6.39%-0.56%-1.99%CVACCureVac0.00%0.00%0.00%0.00%-15.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALNYAlnylam Pharmaceuticals 2.85Moderate Buy$463.1365.33% UpsideBMRNBioMarin Pharmaceutical 2.75Moderate Buy$88.6761.41% UpsideCVACCureVac 1.50Reduce$5.5018.03% UpsideCurrent Analyst Ratings BreakdownLatest CVAC, BMRN, and ALNY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026BMRNBioMarin Pharmaceutical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)6/4/2026ALNYAlnylam Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$510.005/29/2026BMRNBioMarin Pharmaceutical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)5/22/2026BMRNBioMarin Pharmaceutical Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$116.00 ➝ $111.005/19/2026ALNYAlnylam Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$380.005/19/2026BMRNBioMarin Pharmaceutical Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$85.00 ➝ $80.005/19/2026BMRNBioMarin Pharmaceutical CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$75.005/18/2026ALNYAlnylam Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/18/2026BMRNBioMarin Pharmaceutical CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/18/2026BMRNBioMarin Pharmaceutical HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$55.00 ➝ $50.005/15/2026BMRNBioMarin Pharmaceutical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)(Data available from 6/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALNYAlnylam Pharmaceuticals$3.71B10.07$2.72 per share102.93$5.97 per share46.92BMRNBioMarin Pharmaceutical$3.24B3.27$2.82 per share19.50$31.68 per share1.73CVACCureVac$70.74M14.78$0.99 per share4.73$3.36 per share1.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALNYAlnylam Pharmaceuticals$313.75M$3.6676.7026.63N/A11.72%85.76%10.32%7/30/2026 (Estimated)BMRNBioMarin Pharmaceutical$348.90M$1.3740.129.830.428.29%6.50%5.07%8/3/2026 (Estimated)CVACCureVac$175.50M$0.726.47N/AN/A199.92%-23.03%-19.09%N/ALatest CVAC, BMRN, and ALNY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/30/2026Q1 2026ALNYAlnylam Pharmaceuticals$0.8720$1.99+$1.1180$1.51$1.12 billion$1.17 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALNYAlnylam PharmaceuticalsN/AN/AN/AN/AN/ABMRNBioMarin PharmaceuticalN/AN/AN/AN/AN/ACVACCureVacN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALNYAlnylam Pharmaceuticals0.943.133.06BMRNBioMarin Pharmaceutical0.235.814.20CVACCureVac0.033.703.69Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALNYAlnylam Pharmaceuticals92.97%BMRNBioMarin Pharmaceutical98.71%CVACCureVac17.26%Insider OwnershipCompanyInsider OwnershipALNYAlnylam Pharmaceuticals0.86%BMRNBioMarin Pharmaceutical0.85%CVACCureVac2.15%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALNYAlnylam Pharmaceuticals2,770133.51 million132.37 millionOptionableBMRNBioMarin Pharmaceutical3,221193.28 million191.64 millionOptionableCVACCureVac880224.34 million219.52 millionOptionableCVAC, BMRN, and ALNY HeadlinesRecent News About These CompaniesCureVac sues Moderna for patent infringement over COVID-19 vaccinesApril 24, 2026 | reuters.comCureVac (NasdaqGM:CVAC) Valuation After New mRNA Pipeline Progress And Refined Capital Allocation PlanJanuary 22, 2026 | finance.yahoo.comBioNTech Completes CureVac Takeover and Updates Articles of AssociationJanuary 6, 2026 | tipranks.comBioNTech SE (BNTX) Closes the Acquisition of CureVac N.V.December 23, 2025 | insidermonkey.comCureVac's Independent Journey Concludes as BioNTech Secures ControlDecember 20, 2025 | aktiencheck.deABioNTech Completes CureVac Acquisition to Bolster mRNA LeadershipDecember 18, 2025 | tipranks.comCureVac NV (CVAC): A bull case theoryDecember 4, 2025 | msn.comBioNTech Achieves Minimum Condition in CureVac Exchange OfferDecember 3, 2025 | globenewswire.comCureVac N.V. (CVAC) Shareholder/Analyst Call Prepared Remarks TranscriptNovember 28, 2025 | seekingalpha.comCureVac Shareholders Approve BioNTech Exchange OfferNovember 26, 2025 | tipranks.comBioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025,November 26, 2025 | caledonianrecord.comCEQS-News: CureVac Announces Voting Results of Extraordinary General Meeting (deutsch)November 25, 2025 | boerse-online.deBCureVac Announces Voting Results of Extraordinary General MeetingNovember 25, 2025 | accessnewswire.comAHow Investors May Respond To CureVac (CVAC) Reporting Sharp Decline in Quarterly SalesNovember 25, 2025 | finance.yahoo.comCureVac Reports Q3 2025 Financial Results and UpdatesNovember 24, 2025 | tipranks.comCureVac reports Q3 EPS EUR 1.21 vs. EUR 1.51 last yearNovember 24, 2025 | msn.comCureVac Reports Q3 2025 Financials and BioNTech Transaction ProgressNovember 24, 2025 | tipranks.comCureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business UpdatesNovember 24, 2025 | accessnewswire.comACureVac (NasdaqGM:CVAC): Exploring Valuation After Strong Share Price Gains in 2024November 16, 2025 | finance.yahoo.comCureVac’s New mRNA Study: A Potential Game-Changer in Lung Cancer TreatmentOctober 27, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCVAC, BMRN, and ALNY Company DescriptionsAlnylam Pharmaceuticals NASDAQ:ALNY$279.59 -2.31 (-0.82%) As of 03:45 PM Eastern This is a fair market value price provided by Massive. Learn more.Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.BioMarin Pharmaceutical NASDAQ:BMRN$54.81 -0.31 (-0.57%) As of 03:45 PM Eastern This is a fair market value price provided by Massive. Learn more.BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.CureVac NASDAQ:CVAC$4.66 0.00 (0.00%) As of 06/16/2026CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Meta and Cloud Computing: Real Potential, or a Shot in the Dark? Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Fox Captures The Living Room With $22B Roku Buy Dave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround Plan Microsoft’s Xbox Problem Is Bigger Than a Console War Could a Tesla-SpaceX Merger Be Closer Than Investors Think? After SpaceX, Amazon Could Be The Next Best Space Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
